Answers are grounded in this paper and cite their sources.
Retrospective analysis evaluates infection outcomes in CAR T-cell therapy users of corticosteroids and tocilizumab, indicating heightened risk.
e19007 Background: Corticosteroids and tocilizumab are frequently used to manage cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor T-cell (CAR-T) therapy. However, their impact on post-infusion complications remains uncertain. We aimed to evaluate the association between corticosteroid or tocilizumab exposure and outcomes after CAR-T therapy. Methods: A retrospective multicenter analysis was performed using publicly available data from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry (P-6093, Wudhikarn et al.), limited to patients who received axi-cel. Patients receiving corticosteroids and/or tocilizumab following CAR-T infusion were compared against those who did not. The primary outcome was 100-day infection incidence (overall, bacterial, viral, and fungal). Secondary outcomes included overall survival (OS), neutrophil engraftment, and infection-related mortality (IRM). Baseline characteristics were compared using chi-square and t-tests. Associations between corticosteroid/tocilizumab use and outcomes were assessed using Cox proportional hazards models adjusted for age, Karnofsky performance status (KPS), hematopoietic cell transplantation comorbidity index (HCT-CI), disease category, prior HCT, and transformed lymphoma status. Statistical significance was defined as p<0.05. Results: Among 2,749 CAR-T recipients, 1,873 (68.1%) received corticosteroids or tocilizumab. These patients were older (60.2±12.6 vs 58.1±13.4 years; p<0.001), had lower KPS (20.4% vs 15% with KPS < 80; p<0.001), and more frequently had transformed lymphoma (74% vs 64%; p<0.001) compared to those who did not. Corticosteroid/tocilizumab use was independently associated with higher 100-day overall infection incidence (HR 1.64; 95%CI 1.33–2.01; p<0.001), bacterial infections (HR 1.92; 95%CI 1.46–2.52; p<0.001), and fungal infections (HR 2.47; 95%CI 1.25–4.88; p=0.009). Viral infections were not significantly different between the two groups (HR 1.34; 95%CI 0.99–1.80; p=0.057). The use of corticosteroids/tocilizumab was also significantly associated with increased infection-related mortality (HR 4.24; 95%CI 1.29–13.94; p=0.018). However, there was no statistically significant difference in terms of overall survival (HR 1.11; 95%CI 0.96–1.27; p=0.149) or neutrophil engraftment (HR 0.92; 95%CI 0.84–1.01; p=0.089). Conclusions: Corticosteroid and tocilizumab use following CAR-T therapy is independently associated with an increased risk of bacterial and fungal infections and higher infection-related mortality, highlighting the importance of antimicrobial prophylaxis and infection surveillance.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: